Shire (pharmaceutical company)

Shire Plc

Type	Public limited company
Traded as	LSE: SHP NASDAQ: SHPG NASDAQ-100 Component
Industry	Pharmaceuticals
Predecessor	Shire Pharmaceuticals Group Plc
Founded	1986 (1986)
Headquarters	Registered Office: St Helier, Jersey Corporate HQ: Dublin, Ireland UK Operations: Basingstoke, England
Key people	Susan Kilsby (Chairman) Flemming Ørnskov, MD (CEO)
Revenue	$6,416.7 million (2015)[1]
Operating income	$1,419.5 million (2015)[1]
Net income	$1,303.4 million (2015)[1]
Number of employees	5,300 (2014)[2]
Website	www.shire.com

Shire Plc is a Jersey-registered, Irish-headquartered global specialty biopharmaceutical company. Originating in the United Kingdom with an operational base in the United States, its brands and products include Vyvanse, Lialda, and Adderall XR. Shire has its primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. Shire has a secondary listing on NASDAQ.

Shire is a global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. The company's products are available in more than 100 countries across core therapeutic areas including Hematology, Immunology, Neuroscience, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; a growing franchise in Oncology; and an emerging, innovative pipeline in Ophthalmics.

The original corporate headquarters was located in Basingstoke, Hampshire, England. Main offices are located in Dublin, Ireland, the United States in Cambridge, Massachusetts and Chicago, Illinois and in Zug, Switzerland. In addition, Shire owns a manufacturing site in Lexington, Massachusetts and building a new manufacturing facility in Dublin, Ireland. It announced in November 2013 that it would be further reducing its presence in the UK.^[3]

History

Location in Lexington, Massachusetts

Shire was founded in 1986 in the UK by four entrepreneurs. These four entrepreneurs were Harry Stratford, Dennis Stephens, Peter Moriarty, and Geoff Hall.^[4] It was first listed on the London Stock Exchange in 1996. Shire's initial products were calcium supplements (Calcichew-D₃) for patients seeking to treat or prevent osteoporosis. In 1997 the company acquired Pharmavene for £105 million in order to access Pharmavene's drug delivery methods.^[5] Later in the same year Shire acquired Richwood Pharmaceutical Company, forming Shire-Richwood Inc.^[6]

In 2001 the company acquired Biochem Canada.^[7] Shire's next acquisition didn't come until 2005 when it acquired Transkaryotic Therapeutics^[8] and two years later - in 2007 - New River Pharmaceuticals Inc, for a then company record of $2.6 billion.^[9] With the purchase of New River, Shire gained access and ownership of Vyvanse. A year late the company acquired the German company Jerini, for $521 million. Jerini focused on treating hereditary angioedema.^[10]

In 2008, in reaction to new taxation measures announced by the Labour Party in the treatment of royalties on patents, the company moved its tax domicile to Dublin, Ireland.^[11]

2010 saw a change in company strategy, with the company seeking to expand through mergers and acquisitions - culminating in the company becoming one of the most acquisitive in the industry. In 2010 the company acquired Movetis, a Belgian company focusing on gastrointestinal products for $565 million,^[12] a year later it acquired regenerative medicine manufacturer Advanced BioHealing.^[13] In 2012 the company acquired FerroKin BioSciences for $325 million along with FerroKins lead iron chelator - FBS0701.^[14] 2013 saw the company complete its highest number of acquisitions with Lotus Tissue Repair, Inc. (lead compound, ABH001),^[15] SARcode Bioscience Inc.,^[16] with the last being ViroPharma.^[17] At $4.2 billion, ViroPharma set a new company record.^[18] In 2014 Shire acquired two rare disease drug companies; Fibrotech^[19] with its antifibrotic compounds for $75 million and Lumena, a company researching rare gastro-intestinal and hepatic compounds, for $260 million.^[20]

Aborted AbbVie takeover

On 20 June 2014, Shire rejected a takeover attempt by AbbVie. AbbVie offered £46.11 per share (£27.3 billion or $46.5 billion in total).^[21] On 8 July the offer was increased to $51.5 billion.^[22] On 18 July, it was announced that AbbVie would acquire Shire for $54.8 billion.^[23] On 15 October, news broke suggesting AbbVie was reconsidering their proposed takeover deal due to changes in US "Tax Inversion" law ^[24] and on 16 October AbbVie's board recommended that shareholders vote against the deal.^[25] This news sent Shire's share price down over 27%, however AbbVie will be subject to a $1.6 billion break up fee, payable to Shire.^[26] On 21 October the merger was called off.^[27]

In 2015, NPS Pharmaceuticals was acquired for $5.2 billion, bringing along its rare disease drugs Gattex and Natpara.^[28] The company also acquired, later in the same year Meritage Pharma for $245 million, Foresight Biotherapeutics for $300 million^[29] and Dyax for $6.5 billion.^[30][31] The purchases bolstered Shires Gastro-intestinal and rare disease sectors, with Phase-III ready treatment - Budesonide - for the treatment of eosinophilic esophagitis. As well as expanding the company's pipeline with a late-stage treatment candidate for infectious conjunctivitis with lead candidate FST-100 and increased the companies rare disease catalogue with Dyax’s portfolio of plasma kallikrein inhibitors against hereditary angioedema (led by the approved drug Kalbitor and the Phase III DX-2930). In January 2016, the company made its most significant purchase, with the $32 billion acquisition of Baxalta, creating the largest global biotech company focused solely on rare diseases.^[32]

Investors

As of 31 December 2015, investors holding more than 0.5% of total outstanding shares include the Harbor Capital Appreciation Fund (with 1.17%), and the institutional investors Jennison Associates (3.59%), Paulson & Company (3.42%), Waddell & Reed (1.81%), Fidelity (1.28%), T. Rowe Price Associates (0.84%), FMR (0.79%), Goldman Sachs Group (0.53%), and Invesco (0.50%).^[33]

Acquisition history

Click show to reveal an illustration of Shire mergers, acquisitions, spin-offs, and historical predecessors, complete as of this date.

Products

The Annual Revenue figures in the following table were drawn from the company's 2015 full year report of preliminary results.^[1]

A container of Adderall XR

Licences & Royalties

In July 2014, Shire licensed the rights to the investigational Hunter syndrome compound, AGT-182, from ArmaGen for up to $225 million.^[55]

The Annual Revenue figures in the following Table were drawn from the company's Q4 report of preliminary results.^[1]

Corporate leadership

As of March 2016, the leadership of the company is provided by its CEO, Flemming Ørnskov, who has been the company's chief executive officer since mid-2013.^[56] Ginger Gregory as Chief Human Resources Officer, Jeffrey Poulton as CFO, and Philip Vickers as Head of R&D.^[57] James Bowling vacated his position as interim CFO in the aftermath of the collapse o the AbbVie inversion deal.^[58] The Chair of Shire's Board of Directors is Susan Kilsby.^[59]

See also

• Pharmaceutical industry in the United Kingdom

References

External links

• Official website
• Yahoo profile

• • Business data for Shire: Google Finance
  • Yahoo! Finance
  • Reuters
  • SEC filings

Pharmaceutical and biotechnology industry in the United Kingdom
Manufacturing in the United Kingdom Economy of the United Kingdom
companies	current AAH Pharmaceuticals Alliance Boots Astex AstraZeneca (MedImmune) BTG Cyclacel Dechra Pharmaceuticals GE Healthcare Genus GlaxoSmithKline Hikma Pharmaceuticals Indivior MacFarlan Smith Norbrook Group Oxford BioMedica Pfizer UK Phytopharm Proximagen Shire Silence Therapeutics TBS GB Unipath Vectura Group Vernalis ViiV Healthcare defunct Allen & Hanburys Amersham Beecham Group Cambridge Antibody Technology Celltech Chiroscience Distillers Company Fisons Glaxo Wellcome ICI Reliant Pharmaceuticals Renovo Zeneca
government and regulatory bodies	Commission on Human Medicines Department of Health European Directorate for the Quality of Medicines European Medicines Agency Medicines and Healthcare Products Regulatory Agency National Collaborating Centre for Mental Health National Patient Safety Agency Pharmaceutical Price Regulation Scheme Pharmaceutical Society of Northern Ireland General Pharmaceutical Council Scottish Medicines Consortium Veterinary Medicines Directorate
industry and professional bodies	Association of the British Pharmaceutical Industry Chemical Industries Association European Federation of Biotechnology European Federation of Pharmaceutical Industries and Associations Faculty of Pharmaceutical Medicine Pharmacists' Defence Association Royal Pharmaceutical Society of Great Britain Worshipful Society of Apothecaries
books and journals	Bandolier Bad Pharma British National Formulary British National Formulary for Children Monthly Index of Medical Specialities The Pharmaceutical Journal
other	British Approved Name British Pharmacopoeia DrugScope European and Developing Countries Clinical Trials Partnership European Pharmacopoeia List of world's largest pharmaceutical companies Pharmaceutical Services Negotiating Committee Wellcome Trust
category

FTSE 100 companies of the United Kingdom   → FTSE 250
3i Admiral Group Anglo American Antofagasta Ashtead Group Associated British Foods AstraZeneca Aviva BAE Systems BHP Billiton BP Babcock International Barclays Barratt Developments British American Tobacco British Land BT Group Bunzl Burberry Capita Carnival Centrica Coca-Cola HBC Compass Group CRH Croda International DCC Diageo Direct Line Group Dixons Carphone easyJet Experian Fresnillo GKN GlaxoSmithKline Glencore Hammerson Hargreaves Lansdown Hikma Pharmaceuticals HSBC Imperial Brands Informa InterContinental Hotels Group International Airlines Group Intertek Intu Properties ITV Johnson Matthey Kingfisher Land Securities Group Legal & General Lloyds Banking Group London Stock Exchange Group Marks & Spencer Mediclinic International Merlin Entertainments Micro Focus International Mondi Morrisons National Grid Next Old Mutual Paddy Power Betfair Pearson Persimmon Polymetal International Provident Prudential Randgold Resources Royal Bank of Scotland Reckitt Benckiser RELX Group Rio Tinto Group Rolls-Royce Royal Dutch Shell Royal Mail RSA Insurance Group Sage Group J Sainsbury Schroders Severn Trent Shire Sky Smith & Nephew Smiths Group SSE Standard Chartered Standard Life St. James's Place Taylor Wimpey Tesco Travis Perkins TUI Unilever United Utilities Vodafone Whitbread Wolseley Worldpay WPP